Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is among the 10 Fastest Growing NASDAQ Stocks to Buy.

On February 25, 2026, Oppenheimer expert Andreas Argyrides raised the firm’s terms people connected Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to $105 from $95 and maintained an Outperform standing pursuing quarterly results. Management besides provided first-time FY26 nett merchandise income guidance of $670M–$700M for XDEMVY, representing a year-over-year summation of $230M driven by caller diligent demand, wide payer coverage, and effectual direct-to-consumer efforts. The expert said the outlook puts XDEMVY connected way to execute much than $2B successful highest U.S. sales.

Also connected February 25, 2026, Guggenheim raised its terms people connected Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) to $90 from $87 and reiterated a Buy standing aft the institution reported what the steadfast described arsenic “strong” 2025 results. The expert noted that with 2026 income guidance of $670M–$700M and lone a tiny information of the estimated 25M diligent Demodex blepharitis marketplace penetrated, the institution appears “well-positioned for sustained growth.”

On February 23, 2026, Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) reported Q4 EPS of (20c), compared with statement estimates of (13c). The institution reported Q4 gross of $151.67M, supra the $144.56M statement estimate. CEO and Chairman Bobak Azamian said XDEMVY has driven “a cardinal displacement successful oculus care,” noting that the institution has built wide entree and established a increasing franchise wrong 2 years of launch. Azamian added that the merchandise validates the company’s exemplary of integrating science, commercialized execution, and strategical investment, and that the institution plans to use the aforesaid model crossed its pipeline successful ocular rosacea and Lyme illness prevention.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is simply a commercial-stage biopharmaceutical institution focused connected the improvement and commercialization of therapeutic candidates for oculus attraction successful the United States.

While we admit the imaginable of TARS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey connected Google News.